🇺🇸

US SEC Filing Intelligence

Daily AI-powered analysis of SEC EDGAR filings, FDA approvals, and US regulatory disclosures. Investment signals, risk flags, and sector themes for US markets.

·daily

US Material Events SEC 8-K Filings — March 25, 2026

Across 50 SEC 8-K filings from March 25, 2026, dominant themes include widespread board and executive transitions (24 instances of appointments, resignations, retirements across firms like Brand Engagement, Ingredion, HBT Financial, Comstock, Conduent, etc.), signaling proactive governance refreshes amid strategic pivots; robust debt management with 8 credit amendments/extensions (Cipher Mining, Synergy CHC, Senior Credit, Waste Management, Albemarle) enhancing liquidity; active M&A and asset transactions (Sandisk $1B Nanya stake, Fresh Del Monte $285M acquisition, Terns $6.7B Merck buyout, Hecla $160M mine sale); and financings (Apogee $377M equity, Blue Water $125M SPAC IPO, Ballston Spa $26M notes). Period-over-period trends are sparse but notable: Maze Therapeutics cash runway extended 83% YoY to $360M (runway to 2028) despite net loss widening to $131.1M from $52.2M profit (R&D +30% YoY, G&A +31%); CIMG Q1 FY2026 revenue exploded to $15.8M from $23k YoY (+69,000%); Generac FY2025 sales $4.2B with Residential EBITDA $558M. Positive sentiment prevails (28/50 filings), especially biotech/pharma (Maze Phase 2 success, Terns M&A) and energy/mining deleveraging; portfolio implications favor monitoring biotech catalysts and governance-improved names for alpha, while watching leadership vacuums and mixed financials like Maze/CIMG delisting risks.

50 high priority50 total filings
·daily

US SEC Filings Daily Market Digest — March 25, 2026

Across 50 SEC filings for March 25, 2026, overarching themes include robust revenue growth in tech/software (e.g., UiPath +13% YoY, Pure Storage +16%, Braze +24.4%, AAR +25%) offset by rising operating expenses and margin pressures in 8/15 growth companies (avg OpEx +15-30% YoY), SPAC trust erosion from redemptions (e.g., Concord -99.6%, byNordic -53%), and positive capital returns via dividends (Zedge +25%, Rentokil +4%) and buybacks (News Corp $1B program). M&A/deals signal conviction (Sandisk $1B investment at 15% discount, Thermon/CECO synergies), while biotech turnarounds (Energous rev +633%, Maze Phase 2 success) contrast energy/mining weakness (CoJax rev flat, Spectral AI -33.6%). Portfolio-level trends show 12/20 annual reports with net losses narrowing (avg -20% YoY) but cash burn persisting in 7/10 SPACs; sentiment mixed/neutral in 70%, positive in growth outliers. Critical developments: Stratus liquidation ($29-37/share potential), Mobix reverse split approval, UiPath profitability milestone imply tactical opportunities amid quiet M&A acceleration. Implications: Favor tech growth names with cash flow inflection, monitor SPAC deadlines/redemptions for distress plays.

31 high priority19 medium50 total filings
·daily

Global High-Priority Regulatory Events — March 25, 2026

Across 50 filings in the 'Global High Priority Market Events' stream, dominant themes include a surge in M&A/takeover activity (e.g., Merck's $6.7B Terns acquisition at 31% premium, Thermon-CECO merger), proxy statements signaling May 2026 annual meeting cluster for governance votes, SPAC trust dynamics with heavy redemptions eroding balances, and Indian insolvency proceedings amid regulatory actions. Period-over-period trends show revenue growth averaging +16% YoY in reporting tech/software firms (e.g., Pure Storage +16%, UiPath +13%, Braze +24%, AAR +25%) but declines in R&D/biotech (Spectral AI -34%, Kiora 100% drop); margins mixed with compression in 6/15 cases (avg -150bps) due to opex rises, offset by profitability turnarounds (UiPath to +4% op margin). Critical developments like Nasdaq delisting risks (SOBR), pledge releases (Indian Hume 22% shares), and product launches (Sterlite HCF) highlight takeover arb opportunities and deleveraging. Portfolio-level patterns reveal bullish M&A in pharma/tech (5 deals), bearish insolvencies (4 cases), and neutral trading window closures (5 Indian firms) pre-results; capital returns strong in housing/insurance (Century $178M, Enact $500M). Implications: Prioritize M&A catalysts Q2 2026 closes, monitor SPAC liquidations, and favor software growth outliers amid proxy-driven volatility.

50 high priority50 total filings
·monthly

US Pre-Market SEC Filings Roundup — March 25, 2026

Across 50 overnight SEC filings, dominant themes include robust revenue growth in tech/AI firms (e.g., Pure Storage +16% YoY, Braze +24% YoY, Energous +633% YoY) offset by widespread margin compression and operating losses (8/15 tech filings showed opex rises >15% YoY), SPAC distress with heavy redemptions eroding trust balances (e.g., Concord Acquisition 99.6% trust drop), and positive M&A/deal momentum (Sandisk $1B investment, Thermon/CECO merger). Period-over-period trends reveal 12/25 revenue reporters posting YoY growth averaging +20% but only 4 achieving profitability flips (UiPath, AAR Corp); capital allocation leans toward dividends/buybacks (Zedge +25%, News Corp $1B program) amid mixed sentiments (22 mixed, 12 positive). Critical developments like Stratus Properties' liquidation plan (est. $29-38/share) and Maze Therapeutics' Phase 2 success signal high-volatility opportunities, while auditor changes (Brilliant N.E.V.) and litigation (C3.ai partial dismissal) flag governance risks. Portfolio-level patterns show tech outpacing resources/energy (avg revenue +18% vs flat/declining), with forward catalysts clustered in Q2 2026 (mergers, trials, meetings). Implications favor tactical longs in scaling tech/M&A plays and shorts on SPAC liquidity crunches before market open.

31 high priority19 medium50 total filings
·daily

US Material Events SEC 8-K Filings — March 24, 2026

Across 50 SEC filings from March 24, 2026, a dominant theme is widespread leadership transitions in 22 companies (44%), including 12 positive appointments/promotions (e.g., Rush Enterprises COO, Bitcoin Depot CEO), 8 neutral retirements/resignations, and clustered CFO departures at 5 New Mountain entities, signaling potential continuity risks but often smooth internal successions. Financing activities dominate 18 filings (36%), with positive extensions/increases (e.g., Innodata credit to $50M, Portland GE $350M loan) contrasting mixed covenant waivers/debt restructurings (e.g., FTC Solar $10M repayments, Southland $110M assignment), reflecting liquidity management amid uncertain macro conditions. Capital allocation shines with Robinhood's $1.5B buyback authorization (adding $1.1B capacity) and LSI's accretive $325M acquisition (pro forma EBITDA margin up to 11% from 9.7%), while period trends show mixed results: Velo3D revenue +12% YoY to $46M but margins -1100 bps to -16.1%; Cardlytics pro forma revenue -9% but net losses improved 12-79%. M&A/divestitures in 4 filings (LSI, Cardlytics, Krispy Kreme $160M proceeds) support deleveraging/turnarounds, with positive sentiments in 60% of filings. Portfolio-level implications: Bullish for stable leadership/financing in utilities/fintech, cautious on manufacturing/tech margin pressures; watch H1 2026 catalysts like FTC Solar covenants and Velo3D EBITDA positivity.

50 high priority50 total filings
·daily

US SEC Filings Daily Market Digest — March 24, 2026

Across 50 SEC filings for March 24, 2026, key themes include robust revenue growth in niche sectors like patient affordability (Paysign +40.5% YoY), solar trackers (FTC Solar +110.5% YoY), and infrastructure (Smith-Midland prelim +18-25% FY), contrasted by persistent net losses and margin pressures in biotech, tech services, and media (e.g., Bright Mountain Q4 revenue -8% YoY, gross margin -23%). REITs and utilities shone with strong FFO growth (CareTrust +17% YoY) and rate case settlements (NW Natural +$20.1M Year 1 rev), while multiple debt waivers/amendments (FTC Solar, Inotiv) signal liquidity strains amid high interest expenses. Biotech advancements provide catalysts like Achieve Life's PDUFA on June 20, 2026, and M&A rumors (Estee Lauder-Puig, American Water-Essential Utilities Q1 2027 close) dominate headlines. Galaxy entities' 13F filings reveal massive crypto/mining concentration ($ billions in Bitcoin ETFs, miners like CleanSpark, Core Scientific), indicating bullish institutional conviction in digital assets. Capital allocation favors dividends (Concentrix $0.36 Q, Braemar prefs) and buybacks (News Corp $1B program, Flowco $16.5M repurchase), with shelf offerings/ATMs (Artelo, Aardvark $150M) for fundraising. Overall, mixed sentiment prevails (28/50 mixed/neutral), with portfolio-level trends showing revenue acceleration (avg +30% YoY in 8 growth names) but EBITDA/margin volatility, urging focus on catalysts amid delisting risks in microcaps.

22 high priority28 medium50 total filings
·daily

Global High-Priority Regulatory Events — March 24, 2026

Across 50 filings in the Global High Priority Market Events stream, dominant themes include ongoing insolvency proceedings in 6+ Indian firms (e.g., Future Lifestyle, Punj Lloyd, Unitech International), signaling distress in retail, pharma, and construction sectors; multiple open offers/takeovers (Rekvina Labs, Photon Capital, Aar Shyam) indicating consolidation plays; and widespread trading window closures starting April 1, 2026, ahead of Q4/FY2026 earnings for energy/refinery firms like MRPL, Godavari, Jagsonpal. US-centric 10-K/20-F reports show mixed financials: revenue surges (FTC Solar +110.5% YoY to $99.7M, Audax portfolio +46% to $949.8M) offset by widening losses or going concern doubts (Vertical Aerospace operating loss +108% to £127M, Ocean Thermal net loss $69.3M), while capital returns shine with TVS Motor's ₹570 Cr dividend (₹12/share) and Arch Capital's $1.9B buybacks. Period-over-period trends reveal improving gross margins (FTC Solar -0.9% vs -26.6% prior) but rising op expenses/R&D in tech/energy (Vertical R&D +20% YoY); insider policies strict but no transaction data signals conviction shifts. Portfolio-level, 7/15 annual reports show revenue growth averaging +45% YoY but net losses in 9/15 (avg widening 20-100%), with M&A/amalgamations (Torrent-JB Chemicals) and ATM facilities (Aardvark $150M) as catalysts. Implications: monitor Indian insolvencies for distress alpha, US solar/energy for turnaround bets, and earnings catalysts mid-April-May for volatility.

50 high priority50 total filings
·monthly

US Pre-Market SEC Filings Roundup — March 24, 2026

Overnight SEC filings from March 23-24, 2026, reveal mixed financial momentum across US equities, with standout revenue accelerations in infrastructure (Smith-Midland Q4 +25% YoY to $22-24M, FY +18% to $92-94M) and solar (FTC Solar FY2025 +110.5% to $99.7M), offset by persistent net losses and operational pressures in 7/15 key 10-K/20-F reporters (e.g., Vertical Aerospace op loss +108% to £127M despite net profit swing). REITs and private credit funds shine with CareTrust REIT Normalized FFO +17% YoY to $1.76/share and record $1.764B cap deployment, Audax portfolio +46% to $949.8M, and Golub $10.2B portfolio at 1.33x leverage. Galaxy entities' 13F series disclose massive crypto/mining concentrations (e.g., $137.8B portfolio Q3 2025 with Core Scientific $19B), signaling bullish conviction amid volatility. Debt restructurings/waivers proliferate (FTC Solar $10M repayments, Inotiv liquidity waiver, Southland $110M assignment), raising liquidity flags in 5 firms, while capital returns persist via buybacks (News Corp $1B program, Flowco 780K shares) and dividends (Braemar prefs, Golub $0.1875/share). M&A speculation emerges (Estee Lauder/Puig talks), and proxies indicate governance stability (QXO/Intel annual meetings May). Portfolio-level trends: 6/10 high-materiality firms show YoY revenue growth averaging +65%, but margins mixed with gross improvements (FTC -0.9% vs -26.6%) amid covenant tightening; watch catalysts like WUTC rate approval Aug 1 and 10-K deadlines.

24 high priority26 medium50 total filings
·daily

US Material Events SEC 8-K Filings — March 23, 2026

Across 50 SEC filings from March 23, 2026, a dominant theme is robust corporate financing activity with 18 companies announcing new or amended credit facilities, debt refinancings, or equity offerings (e.g., $10M RenovoRx raise, $750M Ormat notes, $150M Unusual Machines offering), signaling improved liquidity and access to capital amid maturing prior debts. Leadership transitions dominate 22 filings, mostly orderly (e.g., promotions at Virtuix, retirements at Oil States), though some raise concerns like CEO departures at Mesa Labs and SiriusPoint. M&A and divestitures advanced positively (Coeur Mining acquisition boosting 2026 gold production 80% YoY to 680-815koz, Everest Group sale), alongside capital returns (Coeur $750M buyback + inaugural dividend). Period-over-period highlights include Sutro Biopharma's FY2025 revenue +65% YoY to $102.5M, net loss -16% to $191.1M, and RenovoRx's $900k revenue in 9M2025; however, cash burns persist in biotechs. Sector patterns show mining/energy strength (production guidance up, refinancings), financial/healthcare financing surge, but liquidity strains in smaller caps (MSP Recovery advances). Implications: Bullish for refinancings extending maturities (avg to 2029+), watch biotech catalysts, portfolio tilt to miners with buybacks.

50 high priority50 total filings
·daily

US SEC Filings Daily Market Digest — March 23, 2026

Across 50 SEC filings dated March 23, 2026, key themes include mixed financial performance in 2025 10-Ks with 7/15 reporting revenue growth (avg +30% YoY in winners like Finwise +31% assets, Idaho Strategic +65% concentrate sales) contrasted by sharp declines in 5/15 (avg -20% YoY, e.g., Aterian -30%, Ashford Hospitality -6% revenue, -200% net loss widening); robust M&A progress in 5 filings (Thermon/CECO synergies >$40M, Sealed Air clearances, Mission Produce/Calavo proxies); financing positives (Nortech $15M revolver to 2029, Ormat $750M notes for buybacks/debt repurchase); biotech catalysts (Apogee Phase 2 success, Faraday SEC clearance); and neutral/low-materiality ABS compliance (9/10 trusts). Portfolio-level trends show margin resilience in growth names (Idaho gross margin +1150 bps to 62%) but compression elsewhere (Core Labs op income -4%, Aterian gross -530 bps); capital allocation favors repurchases (Honeywell tender $10B notes, News Corp $1B program, Ormat $25M stock buybacks). Critical implications: monitor M&A closes/delays (April 2026 Sealed Air), delisting risks (Volato NYSE deficiency), and Q2 2026 catalysts (Apogee APEX Part B, Avalo LOTUS trial). Sector outliers highlight mining/gold strength vs consumer product weakness, with overall neutral-to-mixed sentiment (22 neutral, 12 mixed). Actionable now: Favor growth outliers like Finwise BaaS (+160% non-interest income), avoid hospitality drags.

36 high priority14 medium50 total filings
·daily

Global High-Priority Regulatory Events — March 23, 2026

Across 50 filings, a dominant theme is distress in Indian companies with 7 insolvency-related updates (e.g., Educomp fresh CIRP, AGS/Vas/Punj Lloyd/RHFL meetings), signaling prolonged corporate restructurings amid neutral RBI liquidity injections (~₹65K Cr net). US filings show mixed 10-K results: revenue growth in mining/energy (Idaho Strategic +65% YoY, Finwise NI +26%) offset by declines (Aterian -30%, Ashford -6%, Core Labs flat), with positive M&A catalysts (Coeur/New Gold acquisition boosting 2026 gold prod +80%, Thermon/CECO merger synergies >$40M). Capital allocation trends favor shareholder returns (Coeur $750M buyback + dividend, Ormat $25M stock repurchases), while ABS trusts (9 filings) confirm routine compliance with no material issues. Portfolio-level, margins compressed in hospitality/tech (Ashford EBITDAre -6%), but gold miners outperformed on price tailwinds ($3,583/oz realized). Critical implications: monitor Indian insolvency resolutions for turnaround alpha, US M&A for consolidation plays, and delisting risks (Volato). Forward catalysts cluster in late March/April 2026 (NCLT hearings, earnings, compliance plans).

50 high priority50 total filings
·monthly

US Pre-Market SEC Filings Roundup — March 23, 2026

Across 50 overnight SEC filings, dominant themes include mixed 2025 full-year results in 10-Ks with revenue growth in select miners/banks (e.g., Idaho Strategic +64.6% YoY, Finwise +26% net income) offset by declines in consumer/hospitality (Aterian -30.4%, Ashford -5.8% revenue), alongside M&A progress (Thermon/CECO synergies >$40M, Sealed Air regulatory clearances), debt refinancings (Nortech $15M revolver to 2029, Ormat $750M notes), and biotech catalysts (Apogee 52-week data supporting Phase 3 in 2H2026). Portfolio-level trends show 7/15 10-Ks with revenue growth averaging +28% YoY but 5 with net losses widening (avg +45%), margin compression in 4/10 (avg -200bps), and improving balance sheets in 6/10 via debt reduction/cash builds. Positive capital allocation signals like News Corp $1B buybacks and Ormat stock repurchases contrast cyber risks (Heritage incident) and delisting threats (Volato). Critical developments: Faraday Future SEC clearance removes overhang; Apogee AD data positions for $50B market. Implications favor energy/mining longs, M&A arbitrage, caution hospitality/consumer shorts amid pre-market positioning.

36 high priority14 medium50 total filings
·daily

Global High-Priority Regulatory Events — March 22, 2026

Tayo Rolls Limited (Stock Code: 504961) exemplifies a high-priority insolvency event with prolonged Corporate Insolvency Resolution Process (CIRP) ongoing since October 30, 2019, now exceeding 6 years without full resolution. NCLT approved JBVNL's acquisition resolution plan on December 17, 2024, but implementation remains stayed by NCLAT, leading to a deadlock in quarterly and annual statutory compliances for periods ended March 31, 2025. The erstwhile Compliance Officer, Harpreet Kaur Bhamra, cites inaction by Resolution Professional M. Anish Agarwal and Successful Resolution Applicant (JBVNL), compounded by inoperative company email and website. Negative sentiment prevails with 9/10 materiality, signaling severe governance and operational paralysis. No period-over-period financial comparisons, ratios, or operational metrics available due to insolvency stasis, highlighting zero growth or margin trends amid stagnation. Portfolio-level implication: single distressed manufacturing asset underscores risks in unresolved bankruptcies, advising avoidance for long-only investors. Critical market event flags potential delisting or further value erosion for shareholders.

1 high priority1 total filings
·daily

Global High-Priority Regulatory Events — March 21, 2026

Across the 7 filings in the Global High Priority Market Events stream, dominant themes include a full leadership overhaul at Classic Filaments Limited following a successful Open Offer and change in control (2 filings), ongoing Corporate Insolvency Resolution Processes (CIRP) for Remedium Lifecare Limited and Radhagobind Commercial Limited signaling acute distress in healthcare and commercial sectors, minor regulatory resolutions for Burnpur Cement (penalty reversal) and Gujarat Kidney And Superspeciality Limited (fines paid), and an upcoming RBI State Government Securities auction. No explicit period-over-period financial trends (YoY/QoQ revenue, margins) are available across filings, but event-driven metrics highlight debt defaults (e.g., ₹7.47 Cr at Remedium) and penalty reversals/fines (₹1.56L reversed vs. ₹6.60L paid). Critical developments point to takeover completion as a potential turnaround catalyst amid pervasive insolvency risks, with mixed sentiment in control change and uniformly negative tones in insolvencies (materiality 10/10). Portfolio-level patterns reveal heightened credit and governance risks in Indian small-caps, particularly healthcare, warranting avoidance of insolvent names while monitoring post-takeover value unlocks and fixed-income auctions for relative safety.

7 high priority7 total filings
·daily

US Material Events SEC 8-K Filings — March 20, 2026

Across 50 8-K filings from March 20, 2026, the dominant theme is widespread executive churn with 17 instances of resignations, appointments, or transitions (e.g., AIR Industries CEO change, Nu Skin interim CFO), mostly neutral sentiment but signaling potential leadership instability in small/mid-caps. M&A and transaction activity is robust in healthcare/consumer sectors, highlighted by Prestige Consumer's $1.045B accretive Breathe Right acquisition (11x EBITDA multiple, H1 FY27 close) and Embecta's £150M Owen Mumford deal (mixed, accretive post-FY28), alongside KORE's $9.25/share cash merger. Period-over-period trends are sparse but mixed: Merlin Labs +515% YoY revenue to $7.6M (2025 vs 2024) yet net losses +35% to $74.8M; Spruce Biosciences net loss -26% YoY to $39M (FY25 vs FY24) with cash to early 2027; Beasley Broadcast -8.7% revenue CAGR to $206.2M FY25E (vs FY23); Prestige historical +3.4% revenue CAGR FY20-25. Distress signals emerge in Zynex bankruptcy (equity cancellation, delisted to ZYXIQ) and Trinseo covenant waivers post-nonpayment (expire Apr 2026). Positive financing trends include Fortive's $2B rev facility, TG Therapeutics' $750M term loan (SOFR+4.75%), and multiple amendments enhancing liquidity. Overall, actionable alpha in accretive M&A catalysts and takeouts outweigh risks from churn and isolated distress, with healthcare outperforming on growth vs media/energy declines.

50 high priority50 total filings
·daily

US SEC Filings Daily Market Digest — March 20, 2026

Across 50 SEC filings for March 20, 2026, dominant themes include advancing SPAC mergers (CoinShares, Einride, Pelican/Greenland) with high redemptions signaling investor caution, accretive M&A in healthcare (Embecta, Prestige, PSA/NSA), and robust revenue growth in tech/aerospace (Aeva +99% YoY, Firefly +163% YoY) offset by widening losses and yield compression in BDCs/investment firms (avg yield drop to 9.1% from 10.0%). Retail (Dollar General +5.2% YoY sales, +107 bps gross margin) and biotech (Cellectis +61.7% revenue) show resilience, but REITs like Belpointe report surging losses (+68% YoY) amid debt growth (+47%). Aggregate trends: 12/20 financial reporters grew revenue >50% YoY (avg +80%), but 8/12 saw net losses widen (avg +40%), with mixed sentiments in 70% of high-materiality filings. M&A valuations appear reasonable (Prestige 11x EBITDA, Embecta £150M for £69M rev), while SPAC redemptions averaged 60%+. Implications: Opportunities in post-merger listings and accretive deals, risks in dilutive financings and operational cash burns.

38 high priority12 medium50 total filings
·daily

Global High-Priority Regulatory Events — March 20, 2026

Across 50 filings in the 'Global High Priority Market Events' stream, dominant themes include ongoing insolvency proceedings in Indian firms (e.g., AGS Transact, Quadrant Televentures), promoter share acquisitions signaling conviction (DCM Shriram), SPAC mergers with high redemptions (Pelican Acquisition), biotech trial successes (Artelo), and M&A/takeover activity (NSA, Embecta, CoinShares). Period-over-period trends show robust revenue growth in 12/50 filings averaging +90% YoY (e.g., Firefly +163%, Aeva +99%, Belpointe +244%), but persistent net losses widening in 8 cases (avg +50% YoY) amid margin volatility and high R&D/debt costs; gross margins expanded notably in QIAGEN (+1,330 bps to 62.2%). Insider/promoter activity is bullish in 4 Indian firms with +5-10% stake increases, while pledges/encumbrances flag leverage risks. Forward-looking catalysts cluster in Q1-Q2 2026: merger closings, CoC meetings, and trial escalations. Portfolio implications favor monitoring biotech/SPAC turnarounds and avoiding insolvency-exposed names, with alpha in revenue accelerators trading below peers.

50 high priority50 total filings
·monthly

US Pre-Market SEC Filings Roundup — March 20, 2026

Overnight SEC filings reveal robust M&A and SPAC activity, with healthcare deals like Prestige's $1.045B Breathe Right acquisition and Embecta's £150M Owen Mumford buyout signaling sector consolidation, while SPAC mergers (CoinShares, Pelican/Greenland, Einride/Legato) advance amid heavy redemptions (Pelican 63%). Revenue growth dominates period comparisons across 12/50 filings, averaging +80% YoY (e.g., Firefly +163%, Aeva +99%, Cellectis +62%), but 8/12 show widening net losses (avg +40%) due to R&D/opex surges and yield compression in BDCs (avg -0.9%). Margin expansions stand out (QIAGEN gross +1,330bps to 62.2%), contrasting compression elsewhere; activist pressure mounts on Lululemon (Wilson 8.4% stake, criticizing flat FY2026 outlook). Capital allocation leans toward buybacks (News Corp $1B program) and financing (Firefly $1.3B inflows), with forward catalysts clustered in late March (merger closings) and April (earnings, meetings). Portfolio-level: Tech/AI/space names outperform on revenue but lag on profitability; BDCs grow assets +72-83% but face yield/margin erosion. Actionable: Favor accretive M&A targets, monitor SPAC post-merger liquidity.

38 high priority12 medium50 total filings
·daily

US Material Events SEC 8-K Filings — March 19, 2026

Across 50 US SEC filings dated March 19, 2026, dominant themes include aggressive capital raising via equity/debt offerings (e.g., SAB, Reviva, Humacyte, Wolfspeed), M&A and SPAC extensions/amendments (MLCI acquisition, Pyrophyte to Apr 2027, Movano-Corvex merger), credit facility amendments tied to pending mergers (AES, Dayton Power), and board/governance changes (appointments at CVS, RGA, resignations at TripAdvisor, LiveRamp). Period-over-period trends reveal revenue pressures in hospitality (RCI Hospitality -5.5% YoY to $279.4M, Bombshells -29.2% YoY; Ashford pro forma -1.5% YoY to $1.15B) but balance sheet improvements via asset sales/debt paydowns (Ashford $56.8M sale, DevvStream $5.9M net debt reduction). Positive catalysts include accretive deals (Collegium AZSTARYS $650M for >$50M H2 2026 revenue, MLCI +30% FRE), debt refinancings (Wolfspeed $475.9M lower-cost notes), and JV formations (Horizon $100M). Financial stress signals in cannabis (Cannabist forbearance to Mar 25) and microcaps (Scorpius $248K notes) contrast with biotech fundraising for trials (SAB-142, brilaroxazine). Portfolio-level: 12/50 filings show financing stress (debt/notes/forbearance), but 8 accretive M&A/JVs signal consolidation; watch Q2/Q3 closings for alpha.

50 high priority50 total filings
·daily

US SEC Filings Daily Market Digest — March 19, 2026

Across 50 SEC filings for March 19, 2026, key themes include mixed FY2025 financial results with explosive growth in semiconductors (Micron +196% YoY revenue) and biotech (argenx +90% sales), contrasted by declines in digital health (DarioHealth -17% revenue) and energy (Equinor -2.5% revenues). Airlines showed resilience (Republic Airways +13.7% revenue, +32.9% Adj EBITDA), solar outperformed (SUNation +77% Q4 revenue beat), while mining had production gains but cost pressures (Gold Resource + AuEq oz YoY). Capital allocation remains shareholder-friendly with dividends declared (Modiv, Global Net Lease) and News Corp's $1B buyback program ongoing. SPAC extensions (Pyrophyte, Artius II, Rice Acq) signal prolonged deal hunts amid no combinations; RYVYL merger nears approval with 99% yes votes. Routine ABS 10-K compliance across 20+ filings indicates stable servicing with no material issues. Portfolio trend: 7/15 high-materiality firms beat revenue expectations YoY, but 5 saw cash declines; forward catalysts cluster late March (earnings, votes). Implications: Favor growth sectors like semis/biotech; monitor energy/health stress and merger closes for near-term alpha.

37 high priority13 medium50 total filings
← All geographies